Author: laminar

The Spanish government has announced the public grants corresponding to the State Program for research, development and innovation call — geared towards societal challenges and called "Collaboration Challenges of the year 2019". These are instruments to help meet the needs of the Spanish Science, Technology...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text] From the left, top: Adrian McNicholl, Gema Malet, Pablo V. Escribá, Ignacio Larrayoz, Paula Fernández y Roberto Beteta. Seated: Emilce Cano, Rafael Peláez, Catalina Rosselló, Raquel Rodríguez y Manuel Torres. November 20th, 2020 The Spanish government has announced...

Many drugs that are available in the market have something in common, regarding how they make effect: they directly target one or more proteins. And this is not a coincidence. Proteins perform a vast range of functions within the cells of all living organisms that...

Many drugs that are available in the market have something in common, regarding how they make effect: they directly target one or more proteins. And this is not a coincidence. Proteins perform a vast range of functions within the cells of all living organisms that...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Given the good track record of the stock market as an alternative source of financing, the biotechnology company Laminar Pharma is taking its first steps to attract private investors and institutions, by joining...